Akeso Inc. has announced a significant regulatory approval for their innovative treatment, cadonilimab. The China National Medical Products Administration (NMPA) has approved the use of cadonilimab as a first-line treatment for advanced, recurrent, or metastatic cervical cancer as of May 2025. This approval marks an important milestone for Akeso, as cadonilimab, a first-in-class PD-1/CTLA-4 bispecific antibody, has shown significant improvements in progression-free survival and overall survival in various patient subgroups. This development highlights the ongoing impact of cadonilimab in transforming the treatment standards for advanced cervical cancer and underscores its potential global health benefits for women.
免责声明:投资有风险,本文并非投资建议,以上内容不应被视为任何金融产品的购买或出售要约、建议或邀请,作者或其他用户的任何相关讨论、评论或帖子也不应被视为此类内容。本文仅供一般参考,不考虑您的个人投资目标、财务状况或需求。TTM对信息的准确性和完整性不承担任何责任或保证,投资者应自行研究并在投资前寻求专业建议。